Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer

The purpose of this study is to evaluate the efficacy and safety of Qizhu Yuling prescription for postoperative esophagus cancer.

Inclusion Criteria:1. Esophageal cancer without esophagogastric junction pT1-4aN + M0 (stage IIB-IVA) meeting the diagnostic criteria without recurrence or metastasis;2. Patients who have completed adjuvant therapy (including adjuvant radiotherapy, adjuvant chemotherapy, adjuvant chemotherapy + radiotherapy) within 6 months after R0 resection for esophageal cancer;3. ECOG score 0-2;4. 18-75 years old;5. Expected survival ≥ 3 months;6. Subjects voluntarily signed informed consent.Exclusion Criteria:1. Combined with primary tumor at other sites;2. Patients complicated with severe primary diseases of heart, cerebral vessels, liver, kidney and hematopoietic system;3. Patients with mental illness and mental and language disorders;4. Participation in other clinical trials within 3 months;5. Patients with known hypersensitivity or intolerance to study drug.